Markets

DBV Submits BLA For VIASKIN Peanut Patch In Children With Peanut Allergy

September 29, 2026 — 11:24 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - DBV Technologies (DBVT) announced the submission of a Biologics License Application to the U.S. FDA for the VIASKIN Peanut Patch in children aged 4 to 7 years with peanut allergy.

The company has also requested Priority Review. The FDA previously granted Breakthrough Therapy Designation to the VIASKIN Peanut Patch.

The filing is supported by positive results from the Phase 3 VITESSE trial, which enrolled 654 children and is the largest immunotherapy study conducted to date in this patient population.

VIASKIN Peanut Patch uses epicutaneous immunotherapy (EPIT), a non-oral, non-injection approach that delivers small amounts of peanut protein through the skin to help desensitize children with peanut allergy.

DBVT's shares closed Tuesday's trading at $11.55, down 0.77%. In overnight trading, the stock is at $11.76, up 1.82%.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
DBVT

Latest Articles
Data is currently not available